ProfileGDS5678 / 1452851_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 57% 58% 57% 58% 57% 61% 61% 57% 58% 58% 57% 58% 57% 58% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4852457
GSM967853U87-EV human glioblastoma xenograft - Control 23.474158
GSM967854U87-EV human glioblastoma xenograft - Control 33.4664357
GSM967855U87-EV human glioblastoma xenograft - Control 43.42858
GSM967856U87-EV human glioblastoma xenograft - Control 53.4321557
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.742361
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.7099761
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4666457
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4660158
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4719558
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.466157
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4502458
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4653957
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4709658